VEGFA and vitreous hemorrhage: Of the 13 affected eyes, 2 had a history of vitreous hemorrhage, which resolved or cleared after laser monotherapy or vitrectomy combined with anti-vascular endothelial growth factor (VEGF) therapy, making them eligible for SS-OCT and SS-OCTA evaluation.